FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1857708706> ?p ?o ?g. }

• W1857708706 endingPage "5" @default.
• W1857708706 startingPage "5" @default.
• W1857708706 abstract "Staging and response criteria were initially developed for Hodgkin lymphoma (HL) over 60 years ago, but not until 1999 were response criteria published for non-HL (NHL). Revisions to these criteria for both NHL and HL were published in 2007 by an international working group, incorporating PET for response assessment, and were widely adopted. After years of experience with these criteria, a workshop including representatives of most major international lymphoma cooperative groups and cancer centers was held at the 11(th) International Conference on Malignant Lymphoma (ICML) in June, 2011 to determine what changes were needed. An Imaging Task Force was created to update the relevance of existing imaging for staging, reassess the role of interim PET-CT, standardize PET-CT reporting, and to evaluate the potential prognostic value of quantitative analyses using PET and CT. A clinical task force was charged with assessing the potential of PET-CT to modify initial staging. A subsequent workshop was help at ICML-12, June 2013. Conclusions included: PET-CT should now be used to stage FDG-avid lymphomas; for others, CT will define stage. Whereas Ann Arbor classification will still be used for disease localization, patients should be treated as limited disease [I (E), II (E)], or extensive disease [III-IV (E)], directed by prognostic and risk factors. Since symptom designation A and B are frequently neither recorded nor accurate, and are not prognostic in most widely used prognostic indices for HL or the various types of NHL, these designations need only be applied to the limited clinical situations where they impact treatment decisions (e.g., stage II HL). PET-CT can replace the bone marrow biopsy (BMBx) for HL. A positive PET of bone or bone marrow is adequate to designate advanced stage in DLBCL. However, BMBx can be considered in DLBCL with no PET evidence of BM involvement, if identification of discordant histology is relevant for patient management, or if the results would alter treatment. BMBx remains recommended for staging of other histologies, primarily if it will impact therapy. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale, and included in new PET-based response criteria, but CT should be used in non-avid histologies. The definition of PD can be based on a single node, but must consider the potential for flare reactions seen early in treatment with newer targeted agents which can mimic disease progression. Routine surveillance scans are strongly discouraged, and the number of scans should be minimized in practice and in clinical trials, when not a direct study question. Hopefully, these recommendations will improve the conduct of clinical trials and patient management." @default.
• W1857708706 created "2016-06-24" @default.
• W1857708706 creator A5082606841 @default.
• W1857708706 date "2015-03-01" @default.
• W1857708706 modified "2023-10-17" @default.
• W1857708706 title "Staging and response assessment in lymphomas: the new Lugano classification." @default.
• W1857708706 cites W1224611247 @default.
• W1857708706 cites W1791244478 @default.
• W1857708706 cites W1912693401 @default.
• W1857708706 cites W1945262124 @default.
• W1857708706 cites W1963045338 @default.
• W1857708706 cites W1970648523 @default.
• W1857708706 cites W1972151064 @default.
• W1857708706 cites W1972610788 @default.
• W1857708706 cites W1974114089 @default.
• W1857708706 cites W1992575374 @default.
• W1857708706 cites W1998555368 @default.
• W1857708706 cites W2012759826 @default.
• W1857708706 cites W2041629407 @default.
• W1857708706 cites W2055310422 @default.
• W1857708706 cites W2086804941 @default.
• W1857708706 cites W2099899547 @default.
• W1857708706 cites W2103693062 @default.
• W1857708706 cites W2107263178 @default.
• W1857708706 cites W2108083659 @default.
• W1857708706 cites W2111869009 @default.
• W1857708706 cites W2115919161 @default.
• W1857708706 cites W2119147717 @default.
• W1857708706 cites W2127766018 @default.
• W1857708706 cites W2130383144 @default.
• W1857708706 cites W2130669641 @default.
• W1857708706 cites W2131452371 @default.
• W1857708706 cites W2131900456 @default.
• W1857708706 cites W2132855179 @default.
• W1857708706 cites W2133201432 @default.
• W1857708706 cites W2138384559 @default.
• W1857708706 cites W2141681661 @default.
• W1857708706 cites W2142348622 @default.
• W1857708706 cites W2155009647 @default.
• W1857708706 cites W2155283107 @default.
• W1857708706 cites W2169407833 @default.
• W1857708706 cites W2222549821 @default.
• W1857708706 cites W2328676772 @default.
• W1857708706 cites W2554120185 @default.
• W1857708706 cites W2605539363 @default.
• W1857708706 cites W94313875 @default.
• W1857708706 doi "https://doi.org/10.3978/j.issn.2304-3865.2014.11.03" @default.
• W1857708706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25841712" @default.
• W1857708706 hasPublicationYear "2015" @default.
• W1857708706 type Work @default.
• W1857708706 sameAs 1857708706 @default.
• W1857708706 citedByCount "48" @default.
• W1857708706 countsByYear W18577087062015 @default.
• W1857708706 countsByYear W18577087062016 @default.
• W1857708706 countsByYear W18577087062017 @default.
• W1857708706 countsByYear W18577087062018 @default.
• W1857708706 countsByYear W18577087062019 @default.
• W1857708706 countsByYear W18577087062020 @default.
• W1857708706 countsByYear W18577087062021 @default.
• W1857708706 countsByYear W18577087062022 @default.
• W1857708706 countsByYear W18577087062023 @default.
• W1857708706 crossrefType "journal-article" @default.
• W1857708706 hasAuthorship W1857708706A5082606841 @default.
• W1857708706 hasConcept C126322002 @default.
• W1857708706 hasConcept C126838900 @default.
• W1857708706 hasConcept C143998085 @default.
• W1857708706 hasConcept C146357865 @default.
• W1857708706 hasConcept C151730666 @default.
• W1857708706 hasConcept C166957645 @default.
• W1857708706 hasConcept C17744445 @default.
• W1857708706 hasConcept C19527891 @default.
• W1857708706 hasConcept C2776957806 @default.
• W1857708706 hasConcept C2777058707 @default.
• W1857708706 hasConcept C2779134260 @default.
• W1857708706 hasConcept C2779338263 @default.
• W1857708706 hasConcept C2985871740 @default.
• W1857708706 hasConcept C2989005 @default.
• W1857708706 hasConcept C2992779791 @default.
• W1857708706 hasConcept C3116431 @default.
• W1857708706 hasConcept C71924100 @default.
• W1857708706 hasConcept C86803240 @default.
• W1857708706 hasConcept C95457728 @default.
• W1857708706 hasConceptScore W1857708706C126322002 @default.
• W1857708706 hasConceptScore W1857708706C126838900 @default.
• W1857708706 hasConceptScore W1857708706C143998085 @default.
• W1857708706 hasConceptScore W1857708706C146357865 @default.
• W1857708706 hasConceptScore W1857708706C151730666 @default.
• W1857708706 hasConceptScore W1857708706C166957645 @default.
• W1857708706 hasConceptScore W1857708706C17744445 @default.
• W1857708706 hasConceptScore W1857708706C19527891 @default.
• W1857708706 hasConceptScore W1857708706C2776957806 @default.
• W1857708706 hasConceptScore W1857708706C2777058707 @default.
• W1857708706 hasConceptScore W1857708706C2779134260 @default.
• W1857708706 hasConceptScore W1857708706C2779338263 @default.
• W1857708706 hasConceptScore W1857708706C2985871740 @default.
• W1857708706 hasConceptScore W1857708706C2989005 @default.
• W1857708706 hasConceptScore W1857708706C2992779791 @default.
• W1857708706 hasConceptScore W1857708706C3116431 @default.

• next